286 related articles for article (PubMed ID: 33084148)
1. CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y; Harutani Y; Oyanagi J; Akamatsu H; Murakami E; Shibaki R; Hayata A; Sugimoto T; Tanaka M; Takakura T; Furuta K; Okuda Y; Sato K; Teraoka S; Ueda H; Tokudome N; Kitamura Y; Fukuoka J; Nakanishi M; Koh Y; Yamamoto N
Cancer Sci; 2021 Jan; 112(1):72-80. PubMed ID: 33084148
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and predictive roles of plasma C-reactive protein and PD-L1 in non-small cell lung cancer.
Kuusisalo S; Tikkanen A; Lappi-Blanco E; Väisänen T; Knuuttila A; Tiainen S; Ahvonen J; Iivanainen S; Koivunen JP
Cancer Med; 2023 Aug; 12(15):16087-16097. PubMed ID: 37329173
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection.
Wasilewski D; Onken J; Höricke P; Bukatz J; Murad S; Früh A; Shaked Z; Misch M; Kühl A; Klein O; Ehret F; Kaul D; Radbruch H; Capper D; Vajkoczy P; Horst D; Frost N; Bischoff P
J Neurooncol; 2024 Mar; 167(1):155-167. PubMed ID: 38358406
[TBL] [Abstract][Full Text] [Related]
4. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
5. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
9. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Takei S; Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Katayama Y; Nishioka N; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
Front Immunol; 2024; 15():1348034. PubMed ID: 38464519
[TBL] [Abstract][Full Text] [Related]
13. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
15. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
[TBL] [Abstract][Full Text] [Related]
16. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
18. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
20. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]